Experience of Padma 28 in multiple sclerosis

Pomeranian Medical University in Szczecin, Stettin, West Pomeranian Voivodeship, Poland
Phytotherapy Research (Impact Factor: 2.4). 05/1992; 6(3):133 - 136. DOI: 10.1002/ptr.2650060306

ABSTRACT One hundred subjects suffering from a chronic progressive form of multiple sclerosis were randomly divided into two equal groups. Group 1 received Padma 28, two tablets three times a day, and group 2, the control, were treated only symptomatically. Treatment and observation lasted for 1 year. Examinations performed directly prior to the study and in the course of observation included: neurological state, visual and auditory evoked potentials, basic laboratory tests. A positive effect of Padma 28 was observed in 44% of patients with multiple sclerosis in the form of improvement of general condition, increase of muscle strength, decrease or disappearance of disorders affecting sphincters. In 41% of patients with initially an abnormal tracing of visual evoked potentials, an improvement or normalization was achieved. Of patients, who did not receive Padma 28 none felt better, moreover, 40% of them showed a deterioration. Tolerance of the drug was excellent.

1 Follower
  • Source
    • "PADMA 28 has been registered in Switzerland since 1977 by Intercantonal Office for the Control of Medicines as a remedy to alleviate symptoms of claudication, impaired peripheral circulation, pain on walking, leg cramps, and paresthesia. A profitable influence of PADMA 28 was also observed in patients with atherosclerosis and in patients with multiple sclerosis [25] [26]. In 1992, PADMA 28 was registered in Poland. "
    [Show abstract] [Hide abstract]
    ABSTRACT: PADMA 28 is a herbal multicompound remedy that originates from traditional Tibetan medicine and possesses anti-inflammatory, antioxidant, antimicrobial, angioprotecting, and wound healing properties. The aim of the present study was to evaluate the influence of this remedy on immunological angiogenesis and granulocytes metabolic activity in Balb/c mice. Mice were fed daily, for seven days, with 5.8 mg of PADMA (calculated from recommended human daily dose) or 0.085 mg (dose in the range of active doses of other herbal extracts studied by us previously). Results. Highly significant increase of newly formed blood vessels number in ex vivo cutaneous lymphocyte-induced angiogenesis test (LIA) after grafting of Balb/c splenocytes from both dosage groups to F1 hybrids (Balb/c × C3H); increase of blood lymphocytes and granulocytes number only in mice fed with lower dose of remedy; and significant suppression of metabolic activity (chemiluminescence test) of blood granulocytes in mice fed with higher dose of PADMA. Conclusion. PADMA 28 behaves as a good stimulator of physiological angiogenesis, but for this purpose it should be used in substantially lower doses than recommended by producers for avoiding the deterioration of granulocyte function.
    Mediators of Inflammation 06/2013; 2013:853475. DOI:10.1155/2013/853475 · 2.42 Impact Factor
  • Source
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A herbal formula, Badmaev 28, was evaluated in the treatment of an induced attack in a chronic relapsing model of experimental allergic encephalomyelitis (EAE) in SJL/J mice. Chronic EAE was induced by immunization of 8 week old mice with an emulsion of syngeneic spinal cords with incomplete Freund's adjuvant supplemented with Mycobacterium tuberculosis. Therapy with Badmaev 28 was started on day 25 after the immunization, and the formula was administered in the drinking water at doses of 7, 21, 83 and 166 mg/kg/day. The treatment resulted in significantly decreased mortality compared with the untreated control animals and the therapeutic effect occurred in one experiment in a dose-dependent fashion. Based on the experimental results it is difficult to name one particular mechanism responsible for the therapeutic effectiveness of the formula in the EAE model. Rather this protective effect could be explained by a broad protective mechanism of action discussed in the literature as nonspecific resistance (NSR) to the diversified biological and psychological stressors. The increase in NSR characterizes the action of pharmacological compounds termed adaptogens or bioprotectants.
    Phytotherapy Research 05/1999; 13(3):218-21. DOI:10.1002/(SICI)1099-1573(199905)13:3<218::AID-PTR426>3.0.CO;2-D · 2.40 Impact Factor
Show more